FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with propranolol resulted in a rapid improvement (within 7-14 days) in all patients and resolution of the target haemangioma was observed in 36.4% of patients by 3 months.
Croatian: dana) kod svih bolesnika, a kod 36,4% bolesnika unutar 3 mjeseca zabilježeno je iščezavanje ciljnog hemangioma.
English: • Decreased blood pressure.
Croatian: • Snižen krvni tlak,
English: There is no clinical efficacy and safety data in the clinical studies carried out with HEMANGIOL to recommend its initiation in infants and children aged above 5 months.
Croatian: HEMANGIOL-om kako bi se preporučilo započinjanje terapije HEMANGIOL-om kod dojenčadi i djece starije od 5 mjeseci.
English: 1 ml of solution contains 4.28 mg of propranolol hydrochloride equivalent to 3.75 mg of propranolol base.
Croatian: 1 ml otopine sadrži 4,28 mg propranololklorida što odgovara 3,75 mg propranolola u obliku baze.
English: Pregnancy Not relevant.
Croatian: Nije primjenjivo.
English: Blood levels of propranolol may be decreased by co-administration of enzyme inducers like rifampicin or phenobarbital.
Croatian: Istodobna primjena enzimskih induktora kao što su rifampicin ili fenobarbital može sniziti razinu propranolola u krvi.
English: Peripheral coldness
Croatian: Osjećaj periferne hladnoće
English: Investigations
Croatian: Znanstveni zaključci
English: Liver or kidney failure
Croatian: Zatajenje jetre ili bubrega
English: • Step 10: Clean the syringe.
Croatian: • Korak 4. Umetnite štrcaljku
English: 1 ml of solution contains 4.28 mg of propranolol hydrochloride equivent to 3.75 mg of propranolol.
Croatian: 1 ml otopine sadržava 4,28 mg propranololklorida što odgovara 3,75 mg propranolola.
English: 'phaeochromocytoma'.
Croatian: To se naziva „feokromocitom“.
English: Caution should be exercised when patients receiving a beta blocker are administered a dihydropyridine.
Croatian: Potreban je oprez kod primjene dihidropiridina bolesnicima koji uzimaju beta-blokatore.
English: • Constipation, abdominal pain,
Croatian: • Zatvor, bolovi u trbuhu,
English: Only use the oral syringe that is supplied with the medicine to measure and administer the dose.
Croatian: Za mjerenje i primjenu doze koristite samo štrcaljku za usta koja je isporučena zajedno s lijekom.
English: • An oral polypropylene syringe graduated in mg of propranolol, is provided with each bottle.
Croatian: • Uz svaku bocu isporučuje se polipropilenska štrcaljka za usta s oznakama u mg propranolola.
English: DO NOT GIVE HEMANGIOL TO YOUR CHILD UNTIL HE IS BEING CORRECTLY FED AGAIN.
Croatian: NEMOJTE DJETETU DAVATI HEMANGIOL SVE DOK SE PONOVNO NE POČNE PRAVILNO HRANITI.
English: PIERRE FABRE DERMATOLOGIE 45 place Abel Gance F- 92100 Boulogne
Croatian: 45 place Abel Gance
English: • Information on the correct procedure of product preparation and administration including:
Croatian: • Informaciju o pravilnom postupku pripreme i primjene lijeka uključujući: - Upute kako pripremiti otopinu s HEMANGIOL-om - Savjet o prehrani djece tijekom liječenja
English: Propranolol may increase the risk of stroke in PHACE syndrome patients with severe cerebrovascular anomalies by dropping blood pressure and attenuating flow through occluded, narrow, or stenotic vessels.
Croatian: Kod bolesnika s PHACE sindromom s teškim cerebrovaskularnim anomalijama uslijed pada krvnog tlaka i slabljenja protoka kroz okludirane, sužene ili stenozirane krvne žile, propranolol može povećati rizik od moždanog udara.
English: Glucagon then catecholamines should be considered if the patient does not respond appropriately to intravenous fluid.
Croatian: Ako bolesnik ne reagira na odgovarajući način na intravensku tekućinu, moraju se razmotriti primjena glukagona, a zatim kateholamina.
English: Important signs to look after administration of HEMANGIOL Risk of hypotension and bradycardia (low heart rate)
Croatian: Rizik od hipotenzije i bradikardije (usporenog pulsa)
English: If your child gets any side effects, talk to your doctor or pharmacist.
Croatian: Ako primijetite bilo koju nuspojavu kod Vašeg djeteta, potrebno je obavijestiti liječnika ili ljekarnika.
English: In the absence of data, administration of the medicinal product is not recommended to infants with hepatic or renal impairment (see section 4.4).
Croatian: Dojenčad s oštećenjem jetre ili bubrega Uslijed nedostatka podataka, ne preporučuje se primjena lijeka kod dojenčadi s oštećenjem jetre ili bubrega (vidjeti dio 4.4).
English: Dihydropyridines
Croatian: Dihidropiridini
English: Worsening of disease has been reported with beta-blockers in patients suffering from psoriasis.
Croatian: Kod bolesnika oboljelih od psorijaze zabilježeno je da je liječenje beta-blokatorima dovelo do pogoršanja bolesti.
English: Check the dose
Croatian: UPUTA O LIJEKU
English: Hypoglycemic seizure
Croatian: Hipoglikemijska sredstva
English: Hypotension Vasoconstriction Raynaud's phenomenon
Croatian: Raynaudov fenomen
English: Risk of hyperkaliemia
Croatian: Agranulocitoza Hiperkalijemija
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Croatian: Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Nositelj odobrenja:
English: General anaesthesia
Croatian: Opća anestezija
English: • Do not give this medicine to your child if you are taking medicines that must not be used with
Croatian: • Nemojte davati ovaj lijek svom djetetu ako uzimate lijekove koji se ne smiju koristiti istodobno s HEMANGIOL-om (pogledajte „Drugi lijekovi i HEMANGIOL“).
English: Hyperkaliemia
Croatian: Hiperkalemija
English: • Heart conduction or rhythm disorders (slow or uneven heart beats),
Croatian: Rijetke nuspojave (mogu se javiti u manje od 1 na 100 osoba) • Poremećaji srčane provodljivosti i ritma (spori ili neujednačeni otkucaji srca),
English: Urticaria Alopecia
Croatian: Prijavljivanje nuspojava
English: Give HEMANGIOL to your child
Croatian: • Korak 9. Dajte HEMANGIOL djetetu
English: These effects rarely led to definitive treatment discontinuation (see section 4.4).
Croatian: Ti su učinci rijetko doveli do definitivnog prekida liječenja
English: 5 How to store HEMANGIOL
Croatian: 3. Kako davati HEMANGIOL
English: • Step 9.
Croatian: • Korak 10.
English: 10 rue Bouché Thomas ZAC Sud d'Orgemont 49000 ANGERS FRANCE
Croatian: ZAC Sud d'Orgemont
English: How to give HEMANGIOL to your child
Croatian: Kako dati HEMANGIOL
English: Diarrhea Vomiting
Croatian: Krvožilni poremećaji
English: Bradycardia should be diagnosed if the heart rate declines by more than 30 bpm from baseline.
Croatian: Ako srčana frekvencija padne za više od 30 otkucaja u minuti od početne, mora se dijagnosticirati bradikardija.
English: • Step 2.
Croatian: • Korak 1.
English: - Instructions on how to prepare the solution with HEMANGIOL
Croatian: Važni znakovi na koje treba obratiti pažnju nakon primjene lijeka HEMANGIOL
English: This summary was last updated in 06-2015.
Croatian: Sažetak je posljednji put ažuriran u 06. 2015.
English: It is available as tablets (75 mg).
Croatian: Dostupan je u obliku tableta (od 75 mg).
English: In acute coronary syndrome, treatment generally starts with a loading dose of four tablets.
Croatian: U slučaju akutnog koronarnog sindroma, terapija načelno započinje dozom punjenja od četiri tablete.
English: In acute coronary syndrome and atrial fibrillation, Clopidogrel HCS is used together with aspirin, the dose of which should not be higher than 100 mg.
Croatian: U slučaju akutnog koronarnog sindroma i fibrilacije atrija, Clopidogrel HCS koristi se zajedno s aspirinom, čija doza ne smije biti viša od 100 mg.
English: • patients who have recently had a myocardial infarction (heart attack).
Croatian: • bolesnika koji su nedavno pretrpjeli infarkt miokarda (srčani udar).
English: This is then followed by the standard 75mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in unstable angina or non-Q-wave myocardial infarction).
Croatian: Nakon toga slijedi standardna doza od 75 mg jednom na dan tijekom najmanje četiri tjedna (u slučaju infarkta miokarda s „povišenim segmentom ST”) ili do 12 mjeseci (u slučaju nestabilne angine ili „non-Q” infarkta miokarda).
English: The standard dose of Clopidogrel HCS is one 75-mg tablet once a day.
Croatian: Standardna doza lijeka Clopidogrel HCS je jedna tableta od 75 mg na dan.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel HCS.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Clopidogrel HCS.
English: • patients with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
Croatian: • bolesnika s fibrilacijom atrija (nepravilnim brzim kontrakcijama gornjih komora srca) kada se treba primjenjivati s aspirinom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel HCS on 28 October 2010.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Clopidogrel HCS na snazi u Europskoj uniji od 28. listopada 2010.
English: Clopidogrel HCS can be used in patients who are having a heart attack with ‘ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Croatian: Clopidogrel HCS može se primjenjivati u bolesnika koji imaju srčani udar s „povišenjem segmenta ST” (abnormalni rezultat EKG-a ili elektrokardiograma) u slučaju kada liječnik smatra da bi imali koristi od ove terapije.
English: Clopidogrel HCS is used in adults to prevent problems caused by blood clots.
Croatian: Clopidogrel HCS se koristi u odraslih osoba za sprječavanje problema uzrokovanih krvnim ugrušcima.
English: • patients with peripheral arterial disease (problems with blood flow in the arteries);
Croatian: • bolesnika s bolesti perifernih arterija (problemima s protokom krvi u arterijama);
English: Clopidogrel HCS can be given to the following groups of patients:
Croatian: Clopidogrel HCS može se primjenjivati u sljedećih skupina bolesnika:
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel HCS.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Clopidogrel HCS.
English: This means that Clopidogrel HCS is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Croatian: To znači da je Clopidogrel HCS sličan „referentnom lijeku” koji je već odobren u Europskoj uniji pod nazivom Plavix.
English: Clopidogrel HCS can be started between seven days and six months after the stroke;
Croatian: Terapija lijekom Clopidogrel HCS može se započeti od sedam dana do šest mjeseci nakon udara;
English: • patients with acute coronary syndrome (a condition in which blood supply to the heart is reduced), when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Croatian: • bolesnika s akutnim koronarnim sindromom (stanjem pri kojem se smanjuje isporuka krvi u srce), kada se treba primjenjivati s aspirinom (drugim lijekom koji sprječava krvne ugruške), uključujući bolesnike koji imaju ugrađen stent (kratku cijev koja se stavlja u arteriju i sprječava zatvaranje).
English: It is used in patients who have at least one risk factor for events such as a heart attack or stroke, cannot take vitamin-K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Croatian: Koristi se u bolesnika s najmanje jednim čimbenikom rizika za slučajeve poput infarkta miokarda ili moždanog udara koji ne mogu uzimati antagoniste vitamina K (druge lijekove koji sprječavaju krvne ugruške) i koji su izloženi niskom riziku od krvarenja.
English: This means that it helps to prevent blood clots from forming.
Croatian: To znači da sprječava formiranje krvnih ugrušaka.
English: Clopidogrel HCS can be started between a few days and 35 days after the attack;
Croatian: Terapija lijekom Clopidogrel HCS može se započeti od nekoliko dana do 35 dana nakon infarkta;
English: Because Clopidogrel HCS is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine's.
Croatian: Budući da je Clopidogrel HCS generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegovi koristi i rizici isti kao i oni referentnog lijeka.
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a da, kao i u slučaju lijeka Plavix, koristi nadmašuju utvrđeni rizik.
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
Croatian: To sprječava „lijepljenje” trombocita, čime se smanjuje rizik od formiranja krvnih ugrušaka i pomaže pri sprječavanju infarkta miokarda ili moždanog udara.
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel HCS has been shown to have comparable quality and to be bioequivalent to Plavix.
Croatian: CHMP je zaključio da je, u skladu sa zahtjevima EU-a, potvrđeno kako Clopidogrel HCS posjeduje usporedivu kvalitetu te je bioekvivalentan lijeku Plavix.
English: It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a ‘non-Q-wave' myocardial infarction.
Croatian: Može se također primjenjivati u bolesnika koji nemaju abnormalne rezultate EKG-a, ako imaju nestabilnu anginu (snažnu bol u prsima) ili ako su imali „non-Q” infarkt miokarda.
English: Clopidogrel HCS is a ‘generic medicine'.
Croatian: Clopidogrel HCS je „generički lijek”.
English: • patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Croatian: • bolesnika koji su nedavno pretrpjeli ishemijski moždani udar (udar uzrokovan neprimjerenom isporukom krvi u dio mozga).
English: The Committee recommended that Clopidogrel HCS be given marketing authorisation.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Clopidogrel HCS.
English: Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Croatian: Klopidogrel sprječava nakupljanje trombocita tako što inhibira tvar naziva ADP od vezivanja na posebne receptore na površini.
English: Because Clopidogrel HCS is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Croatian: Budući da je Clopidogrel HCS generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje je li lijek bioekvivalentan referentnom lijeku Plavix.
English: What are the benefits and risks of Clopidogrel HCS?
Croatian: Koje su koristi i rizici lijeka Clopidogrel HCS?
English: Clopidogrel HCS is a blood-thinning medicine that contains the active substance clopidogrel.
Croatian: Clopidogrel HCS je lijek za razrjeđivanje krvi koji sadrži djelatnu tvar klopidogrel.
English: When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together).
Croatian: Krv se gruša zbog nakupljanja (povezivanja) posebnih stanica u krvi naziva trombociti.
English: The full EPAR for Clopidogrel HCS can be found on the Agency's website: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Clopidogrel HCS nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Više informacija o terapiji lijekom Clopidogrel HCS pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Other information about Clopidogrel HCS
Croatian: Ostale informacije o lijeku Clopidogrel HCS
English: The active substance in Clopidogrel HCS, clopidogrel, is an inhibitor of platelet aggregation.
Croatian: Djelatna tvar lijeka Clopidogrel HCS, klopidogrel, jest inhibitor nakupljanja trombcita.
English: Why has Clopidogrel HCS been approved?
Croatian: Zašto je Clopidogrel HCS odobren?
English: What is Clopidogrel HCS?
Croatian: Što je Clopidogrel HCS?
English: What is Clopidogrel HCS used for?
Croatian: Za što se Clopidogrel HCS koristi?
English: How is Clopidogrel HCS used?
Croatian: Kako se Clopidogrel HCS koristi?
English: How has Clopidogrel HCS been studied?
Croatian: Kako je Clopidogrel HCS ispitivan?
English: How does Clopidogrel HCS work?
Croatian: Kako djeluje Clopidogrel HCS?
English: Pharmaceutical form Route of administration
Croatian: Farmaceutski oblik Put primjene
English: Member State in EEA
Croatian: Država članica (EU/EGP)
English: INN + Strength
Croatian: Novoizumljeno ime INN + jačina
English: Marketing authorisaton holder
Croatian: Nositelj odobrenja za stavljanje lijeka u promet
English: Meda Pharma Gmbh & Co. Kg
Croatian: Meda Pharma Gmbh & Co.
English: Ratiopharm Gmbh Flupirtinmaleat Ratiopharm
Croatian: Flupirtinmaleat Ratiopharm
English: Farmacêuticos, S.A.
Croatian: Meda Pharma - Produtos Farmacêuticos, S.A.
English: Flupirtinmaleat Tamarang
Croatian: Flupirtinmaleat Tamarang Flupirtin maleat 100 mg kapsule
English: Hormosan Pharma Gmbh
Croatian: Ratiopharm Gmbh
English: Human Medicines Evaluation Division
Croatian: Popis lijekova i prikazi
English: EU/1/17/1176
Croatian: EU/1/17/1176/001 Yargesa
English: 84 x 1 capsules (unit dose)
Croatian: 84 x 1 kapsule (jedinična doza)
English: 100 mg Capsule, hard Oral use blister (PVC/ PCTFE/Alu)
Croatian: Blister (PVC/PCTFE/alu)
English: Yargesa
Croatian: Peroralna primjena
English: EMA Number
Croatian: EMA broj postupka (Novoizumljeno ) ime
English: This slows down the growth and spread of the cancer.
Croatian: Time se usporava rast i širenje raka.
English: The tablets should be taken at the same time every day and consistently with or without food.
Croatian: Tablete treba uzimati u isto vrijeme svakoga dana i uvijek uz obrok ili bez obroka.
English: Further information on Afinitor can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Afinitor.
Croatian: Više informacija o lijeku Afinitor nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Afinitor.
English: Afinitor is available as tablets (2.5, 5 and 10 mg) and the recommended dose is 10 mg once a day.
Croatian: Lijek je dostupan u obliku tableta (2,5, 5 i 10 mg), a preporučena početna doza je 15 ili 10 mg jedanput dnevno.
English: Afinitor received a marketing authorisation valid throughout the EU on 03 August 2009.
Croatian: Lijek Afinitor dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 3. kolovoza 2009.
English: Other information about Afinitor
Croatian: Ostale informacije o lijeku Afinitor
English: What measures are being taken to ensure the safe and effective use of Afinitor?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Afinitor?
English: What is Afinitor and what is it used for?
Croatian: Što je Afinitor i za što se primjenjuje?
English: Doses need to be reduced for patients with liver problems.
Croatian: Doze treba smanjiti u bolesnika koji imaju probleme s jetrom.
English: The doctor may reduce the dose or stop treatment for a short period if the patient has severe or intolerable side effects.
Croatian: Liječnik može smanjiti dozu ili prekinuti liječenje na kraće razdoblje ako bolesnik razvije teške ili nepodnošljive nuspojave.
English: • breast cancer that is advanced (has started to spread) in women who have been through their menopause.
Croatian: • uznapredovalog raka dojke (koji se počeo širiti) u žena koje su prošle menopauzu.
English: It is used when the cancer is metastatic (has spread to other parts of the body) or when it cannot be surgically removed;
Croatian: Primjenjuje se kada je rak metastazirao (proširio se na druge dijelove tijela) ili kada se ne može kirurški ukloniti;
English: The most common side effects with Afinitor (which may affect more than 1 in 10 people) are rash, itching, nausea, decreased appetite, dysgeusia (taste disturbances), headache, weight loss, peripheral oedema (swelling, especially of the ankles and feet), cough, anaemia (low red blood cell counts), tiredness, diarrhoea, weakness, infections, stomatitis (inflammation of the lining of the mouth), hyperglycaemia (high blood glucose levels), hypercholesterolaemia (high blood cholesterol levels), pneumonitis (inflammation of the lungs) and nosebleeds.
Croatian: Najčešće nuspojave lijeka Afinitor (koji se mogu pojaviti u više od 1 na 10 osoba) jesu osip, svrbež, mučnina, smanjen apetit, dizgeuzija (poremećaj okusa), glavobolja, gubitak tjelesne težine, periferni edem (oticanje, osobito gležnjeva i stopala), kašalj, anemija (nizak broj crvenih krvnih stanica), umor, proljev, slabost, infekcije, stomatitis (upala sluznice usne šupljine), hiperglikemija (visoka razina glukoze u krvi), hiperkolesterolemija (visoka razina kolesterola u krvi), pneumonitis (upala pluća) i krvarenja iz nosa.
English: What are the risks associated with Afinitor?
Croatian: Koji su rizici povezani s lijekom Afinitor?
English: Treatment should continue for as long as it works or until side effects become unacceptable.
Croatian: Liječenje treba trajati sve dok je djelotvorno ili dok nuspojave ne postanu neprihvatljive.
English: As for all medicines, data on the use of Afinitor are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Afinitor kontinuirano se prate.
English: Side effects reported with Afinitor are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Afinitor pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The European Medicines Agency decided that Afinitor's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Afinitor nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex'.
Croatian: Everolimus se u tijelu prvo veže za protein naziva FKBP-12 koji se nalazi u stanicama kako bi stvorio „kompleks”.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Afinitor have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Afinitor nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Afinitor must not be used in people who are hypersensitive (allergic) to other rapamycin derivatives (substances with a similar structure to everolimus) or to any of the other ingredients.
Croatian: Lijek Afinitor ne smiju primjenjivati osobe koje su preosjetljive (alergične) na druge derivate rapamicina (tvari čija je struktura slična everolimusu) ili na bilo koje druge sastojke.
English: Afinitor can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the use of cancer treatments.
Croatian: Lijek Afinitor izdaje se samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju raka.
English: Why is Afinitor authorised in the EU?
Croatian: Zašto je Afinitor odobren u EU-u?
English: Afinitor is a cancer medicine used to treat the following cancers:
Croatian: Lijek Afinitor lijek je protiv raka koji se primjenjuje u liječenju sljedećih bolesti:
English: Breast cancer
Croatian: Rak dojke